Titan Pharmaceuticals Inc (TTNP) USD0.001
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. It operates in one business segment, which provides the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. Its product Probuphine implant is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, namely Kappa Opioid Agonist Peptide Program and Nalmefene Development Program. Its kappa opioid agonist peptide (TP-2021) uses ProNeura technology to provide a non-addictive treatment for certain types of pain.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.